Medication Administration Error Involving G-Tube Pantoprazole and Mycophenolate
Summary
The facility failed to maintain a medication error rate of less than 5% during medication pass for one sampled resident. Resident 7 had diagnoses including acute transverse myelitis in demyelinating disease of the central nervous system, GERD, and attention to a gastrostomy tube. The resident’s MDS indicated moderately impaired cognition and dependence on staff for multiple ADLs, and the resident’s eating function was not attempted due to medical condition or safety reasons. During medication administration observation, LVN 5 prepared multiple medications for administration via g-tube, including pantoprazole delayed-release granules and mycophenolate mofetil oral suspension, both scheduled for the same time. LVN 5 crushed several tablets, dissolved them in water, and prepared pantoprazole by mixing the packet in applesauce and then water at bedside before giving it via g-tube. LVN 5 stated it was difficult to administer medications by gravity and that she sometimes had to push the plunger to help medications pass through smoothly. She also stated she usually administered Protonix at the end because of the granules. The resident’s orders showed pantoprazole 40 mg via g-tube twice daily and Cellcept 500 mg via g-tube twice daily. The report states the facility did not provide lab values for mycophenolate mofetil levels. LVN 5 later stated she found the interaction between pantoprazole and mycophenolate and believed they should not be given together because pantoprazole could lower mycophenolate levels. The DON stated the pharmacist had discussed the interaction with the QA nurse and considered it not severe, and the consultant pharmacist stated it was only a cautionary interaction and did not require physician notification. Manufacturer labeling for pantoprazole directed administration via g-tube using apple juice, not applesauce, and identified reduced absorption of mycophenolate mofetil as a clinically relevant interaction. Micromedex identified the interaction as major and noted that concurrent use may reduce mycophenolic acid exposure and decrease efficacy. The facility’s medication administration and unnecessary drugs policies required medications to be administered in accordance with physician orders and state and federal guidelines.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release October 8, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.